Glioma Subtype (Mutant IDH1) May Hold Secret to Increased Success of Immunotherapies

A single common genetic mutation may hold the key to making immunotherapy more effective against gliomas, according to new mouse model findings from the University of Michigan Health Rogel Cancer Center. The flip of a single amino acid from arginine to histidine in a subset of these brain and nervous system tumors sets off a series of changes that, it turns out, sensitizes them to treatment with immune-stimulating therapy, to which they would otherwise be largely resistant.

Login Or Register To Read Full Story